Abid Hussain

Dr Abid Hussain

Future Industries Institute

Future Industries Institute

Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.

Dr Abid Hussain is an emerging research leader in drug delivery and RNA therapeutics, with a Ph.D. in Pharmaceutical Sciences (2019) and a strong track record spanning both industry and academia. His expertise lies in the design and development of lipid-based nanoparticles for targeted delivery of mRNA and siRNA to treat cancer, cardiovascular, respiratory viral infection and metabolic diseases.
As a former Formulation Manager in a leading pharmaceutical company (2019-2021), Dr Hussain led multiple inhalation-based formulation projects, contributing to three internationally patented technologies (WIPO/PCT) and playing a pivotal role in the successful submission of two drug products to the European Medicines Agency (EMA) between 2020–2021.
After transitioning back to academia in 2021, Dr Hussain has made significant contribution to the field of drug delivery technologies, with a more specific recent focus on mRNA therapeutics. As an early career researcher, he has published 29 peer-reviewed articles including in Nature Communications (IF 14.7), Science Advances (IF 14.0), Signal Transduction and Targeted Therapy (IF 40.8), Bioactive Materials (IF 18), Journal of Controlled Release (IF 10.5), Nano Letters (IF 9.6), Plos Pathogen (IF 5.5), Biomaterials Science (5.8), Nano Research (IF 9.6), Molecular Therapy (IF 12.1), and Journal of Nanobiotechnology (10.6). His publications have received over 1500 citations and h-index is 21 (i10-index of 27) (accumulated IF of 250+).
A recent highlight is his recent first authorship publication in Nature Communication (2024) reporting the development of a lipid-based formulation for the delivery of mRNA for the treatment of Hyperuricemia and Gout. This work has significant translational potential and underscores the transformative potential of mRNA therapeutics in addressing metabolic disorders.
His experience working in multidisciplinary teams ideally positions him to contribute significant advances in the RNA therapeutic field. Under the mentoring of Prof Thierry and in collaboration with experts in heart failure (Baker Inst), pancreatic cancer (Garvan Inst) and lung disease (University of Adelaide), Dr Hussain currently leads an innovative research program on targeted lipid nanoparticles for organ-specific RNA delivery, offering possible treatments for cardiovascular diseases, cancer and respiratory viral infection.

Leading projects on optimizing and developing ligand conjugated LNPs for delivery functional mRNA for the treatment of Pancreatic Cancer, Heart Failure by collaborating with Baker Institute and Garvin Institute experts.

Strong collaboration with Cystic Fibrosis Research Group at the University of Adelaide, Dr Hussain is working to develop ligand Conjugated LNPs specifically for pulmonary delivery.

Date Position Institution name
2023 - ongoing Research Ass. University of South Australia
2021 - 2023 Postdoctoral Researcher Beijing Institute of Technology
2019 - 2021 Manager Pharmaceutical Formulation Anovent Pharmaceutical Co., Ltd

Date Type Title Institution Name Country Amount
2015 Scholarship Chinese Government Scholarship Shanghai Jiao Tong University China -

Language Competency
English Can read, write, speak, understand spoken and peer review

Date Institution name Country Title
2015 - 2019 Shanghai Jiao Tong University China PhD

Year Citation
2025 Essola, J. M., Yang, H., Liu, W., Hussain, A., Naeem, A., He, H., . . . Huang, Y. (2025). Tumor suppressor protein-inspired peptide for siRNA delivery and synergistic cancer therapy. Fundamental Research, 5(5), 1920-1929.
DOI Scopus3 WoS3
2024 Zhang, M., Hussain, A., Hu, B., Yang, H., Li, C., Guo, S., . . . Huang, Y. (2024). Atavistic strategy for the treatment of hyperuricemia via ionizable liposomal mRNA. Nature Communications, 15(1), 1-16.
DOI Scopus41 WoS40 Europe PMC25
2024 Moazzam, M., Zhang, M., Hussain, A., Yu, X., Huang, J., & Huang, Y. (2024). The landscape of nanoparticle-based siRNA delivery and therapeutic development. Molecular Therapy, 32(2), 284-312.
DOI Scopus205 WoS189 Europe PMC128
2024 Hussain, A., Wang, M., Yu, D., Zhang, J., Naseer, Q. A., Ullah, A., . . . Zhang, X. (2024). Medical and molecular biophysical techniques as substantial tools in the era of mRNA-based vaccine technology. Biomaterials Science, 12(16), 4117-4135.
DOI Scopus2 WoS2 Europe PMC1
2024 Essola, J. M., Zhang, M., Yang, H., Li, F., Xia, B., Mavoungou, J. F., . . . Huang, Y. (2024). Exosome regulation of immune response mechanism: Pros and cons in immunotherapy. Bioactive Materials, 32, 124-146.
DOI Scopus87 WoS77 Europe PMC62
2024 Liang, Z., Li, C., Gong, X., Ye, G., Jiang, Y., Shi, H., . . . Yang, M. (2024). Development of Glycan-masked SARS-CoV-2 RBD vaccines against SARS-related coronaviruses. Plos Pathogens, 20(9), e1012599.
DOI Scopus7 WoS7 Europe PMC7
2024 Yang, M., Li, C., Ye, G., Shen, C., Shi, H., Zhong, L., . . . Zhao, Y. (2024). Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity. Signal Transduction and Targeted Therapy, 9(1), 40.
DOI Scopus29 WoS28 Europe PMC22
2023 Zhang, M., Hussain, A., Yang, H., Zhang, J., Liang, X. J., & Huang, Y. (2023). mRNA-based modalities for infectious disease management. Nano Research, 16(1), 672-691.
DOI Scopus29 WoS25 Europe PMC20
2023 Hu, B., Kong, S., Weng, Y., Zhao, D., Hussain, A., Jiao, Q., . . . Huang, Y. (2023). Lipid-conjugated siRNA hitchhikes endogenous albumin for tumor immunotherapy. Chinese Chemical Letters, 34(11, article no. 108210), 1-7.
DOI Scopus18 WoS19
2023 Ullah, A., Khan, M., Yibang, Z., Raza, F., Hasnat, M., Cao, J., . . . Liu, D. (2023). Hollow Mesoporous Silica Nanoparticles for Dual Chemo-starvation Therapy of Hepatocellular Carcinoma. Pharmaceutical Research, 40(9), 2215-2228.
DOI Scopus14 WoS14 Europe PMC9
2023 Islam, N., Khan, N. U., Razzaq, A., Menaa, F., Khan, Z. U., Hussain, A., . . . Ni, J. (2023). Loratadine oral bioavailability enhancement via solid dispersion loaded oro-dispersible films: Formulation, characterization and pharmacokinetics. Colloids and Surfaces B Biointerfaces, 230, 113526.
DOI Scopus14 Europe PMC5
2022 Irfan, M., Shahid, A. L., Ahmad, M., Iqbal, W., Elavarasan, R. M., Ren, S., & Hussain, A. (2022). Assessment of public intention to get vaccination against COVID-19: Evidence from a developing country. Journal of Evaluation in Clinical Practice, 28(1), 63-73.
DOI Scopus57 WoS60 Europe PMC37
2022 Hussain, A., Yang, H., Zhang, M., Liu, Q., Alotaibi, G., Irfan, M., . . . Huang, Y. (2022). mRNA vaccines for COVID-19 and diverse diseases. Journal of Controlled Release, 345, 314-333.
DOI Scopus116 WoS90 Europe PMC78
2022 Yu, C., Li, K., Xu, L., Li, B., Li, C., Guo, S., . . . Liang, X. J. (2022). siRNA-functionalized lanthanide nanoparticle enables efficient endosomal escape and cancer treatment. Nano Research, 25(10), 9160-9168.
DOI Scopus20 WoS20
2022 Tuguntaev, R. G., Hussain, A., Fu, C., Chen, H., Tao, Y., Huang, Y., . . . Guo, W. (2022). Bioimaging guided pharmaceutical evaluations of nanomedicines for clinical translations. Journal of Nanobiotechnology, 20(1, article no. 236), 1-31.
DOI Scopus27 WoS23 Europe PMC11
2022 Li, C., Yang, T., Weng, Y., Zhang, M., Zhao, D., Guo, S., . . . Huang, Y. (2022). Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy. Bioactive Materials, 9, 590-601.
DOI Scopus71 WoS66 Europe PMC54
2022 Xu, M., Mao, C., Chen, H., Liu, L., Wang, Y., Hussain, A., . . . Cao, F. (2022). Osteopontin targeted theranostic nanoprobes for laser-induced synergistic regression of vulnerable atherosclerotic plaques. Acta Pharmaceutica Sinica B, 12(4), 2014-2028.
DOI Scopus27 WoS24 Europe PMC16
2022 Hu, B., Li, B., Li, K., Liu, Y., Li, C., Zheng, L., . . . Huang, Y. (2022). Thermostable ionizable lipid-like nanoparticle (iLAND) for RNAi treatment of hyperlipidemia. Science Advances, 8(7, article no. eabm1418), 1-18.
DOI Scopus87 WoS87 Europe PMC73
2022 Ullah, A., Chen, G., Yibang, Z., Hussain, A., Shafiq, M., Raza, F., . . . Qi, X. (2022). A new approach based on CXCR4-targeted combination liposomes for the treatment of liver fibrosis. Biomaterials Science, 10(10), 2650-2664.
DOI Scopus20 WoS18 Europe PMC16
2021 Guo, S., Li, K., Hu, B., Li, C., Zhang, M., Hussain, A., . . . Huang, Y. (2021). Membrane-destabilizing ionizable lipid empowered imaging-guided siRNA delivery and cancer treatment. Exploration, 1(1), 35-49.
DOI Scopus169 WoS155 Europe PMC124
2021 Li, C., Zhou, J., Wu, Y., Dong, Y., Du, L., Yang, T., . . . Huang, Y. (2021). Core role of hydrophobic core of polymeric nanomicelle in edosomal escape of siRNA. Nano Letters, 21(8), 3680-3689.
DOI Scopus103 WoS102 Europe PMC70
2021 Ullah, A., Chen, G., Hussain, A., Khan, H., Abbas, A., Zhou, Z., . . . Liu, D. (2021). Cyclam-modified polyethyleneimine for simultaneous tgfβ sirna delivery and cxcr4 inhibition for the treatment of ccl₄ induced liver fibrosis. International Journal of Nanomedicine, 16, 4451-4470.
DOI Scopus19 WoS21 Europe PMC14
2021 Li, K., Zhang, Y., Hussain, A., Weng, Y., & Huang, Y. (2021). Progress of photodynamic and RNAi combination therapy in cancer treatment. ACS Biomaterials Science and Engineering, 7(9), 4420-4429.
DOI Scopus30 WoS27 Europe PMC16
2019 Khan, M. T., Junaid, M., Mao, X., Wang, Y., Hussain, A., Malik, S. I., & Wei, D. Q. (2019). Pyrazinamide resistance and mutations L19R, R140H, and E144K in Pyrazinamidase of Mycobacterium tuberculosis. Journal of Cellular Biochemistry, 120(5), 7154-7166.
DOI Scopus18 WoS17 Europe PMC17
2019 Hussain, A., & Guo, S. (2019). NIR-triggered release of DOX from sophorolipid-coated mesoporous carbon nanoparticles with the phase-change material 1-tetradecanol to treat MCF-7/ADR cells. Journal of Materials Chemistry B, 7(6), 974-985.
DOI Scopus28 WoS28 Europe PMC19
2017 Zhang, Z., Wang, Y., Xu, S., Yu, Y., Hussain, A., Shen, Y., & Guo, S. (2017). Photothermal gold nanocages filled with temperature sensitive tetradecanol and encapsulated with glutathione responsive polycurcumin for controlled DOX delivery to maximize anti-MDR tumor effects. Journal of Materials Chemistry B, 5(27), 5464-5472.
DOI Scopus33 WoS31 Europe PMC21
2017 Huang, S., Liu, J., Zhu, H., Hussain, A., Liu, Q., Li, J., . . . Guo, S. (2017). PEGylated doxorubicin micelles loaded with curcumin exerting synergic effects on multidrug resistant tumor cells. Journal of Nanoscience and Nanotechnology, 17(5), 2873-2880.
DOI Scopus14 WoS13
2017 Zhu, H., Wang, Y., Hussain, A., Zhang, Z., Shen, Y., & Guo, S. (2017). Nanodiamond mediated co-delivery of doxorubicin and malaridine to maximize synergistic anti-tumor effects on multi-drug resistant MCF-7/ADR cells. Journal of Materials Chemistry B, 5(19), 3531-3540.
DOI Scopus34 WoS27 Europe PMC15
2016 Ullah, F., Ayaz, M., Sadiq, A., Hussain, A., Ahmad, S., Imran, M., & Zeb, A. (2016). Phenolic, flavonoid contents, anticholinesterase and antioxidant evaluation of Iris germanica var; florentina. Natural Product Research, 30(12), 1440-1444.
DOI Scopus79 WoS69 Europe PMC51
2015 Kamal, Z., Ullah, F., Ayaz, M., Sadiq, A., Ahmad, S., Zeb, A., . . . Imran, M. (2015). Anticholinesterse and antioxidant investigations of crude extracts, subsequent fractions, saponins and flavonoids of <i>atriplex laciniata</i> L.: potential effectiveness in Alzheimer's and other neurological disorders. BIOLOGICAL RESEARCH, 48(1), 11 pages.
DOI WoS61 Europe PMC48

Year Citation
2022 Hussain, A. (2022). WO2022006028A2, Pharmaceutical formulation containing combination of m3 antagonist-beta-2 agonist and inhaled corticosteroids. WIPO.
2022 Hussain, A. (2022). US11304901B2, Liposome formulation of fluticasone furoate and method of preparation. US.
2021 Hussain, A., & Cai Gu Huang. (2021). US20210353650A1, Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation. WIPO (PCT).

Cure4CF.

"Developing a one-time gene editing treatment for cystic fibrosis"

Project Duration – 2 years

https://www.cure4cf.org/current-research-projects/research-projects-gene-editing/

Date Role Research Topic Program Degree Type Student Load Student Name
2026 Co-Supervisor Breathing New Life: Engineering Precision mRNA Nanoparticles for Cystic Fibrosis Lung Disease Doctor of Philosophy Doctorate Full Time Mr Ahmed Alnagar
2024 Co-Supervisor 111875-Turning foes into allies: Hijacking myofibroblasts to regenerate cardiac tissues with RNA therapeutics Doctor of Philosophy Doctorate Full Time Dan Yan

Date Role Membership Country
2025 - ongoing Member Australasian Society for Biomaterials and Tissue Engineering Australia

Date Title Type Institution Country
2021 - ongoing Reviewer Peer Review Adelaide Universty -

Date Title URL Description
2021 - 2023 Postdctoral Fellowship (2021-2023) - -

Connect With Me

External Profiles

Other Links